News - Dermatologicals


Current filters:


Popular Filters

100 to 117 of 117 results

Stellar Pharma to sell Apricus MycoVa in Canada


USA-based Apricus Biosciences (Nasdaq: ARI) has signed an exclusive license agreement with Canada’s…

Apricus BioscienceDermatologicalsLicensingMycoVaNorth AmericaPharmaceuticalStellar Pharmaceuticals

FTC stipulates divestments for Valeant acquisitions


Canada’s Valeant Pharmaceuticals International (TSX: VRX) has been ordered by the USA’s Federal…

DermatologicalsDermikMergers & AcquisitionsNorth AmericaPharmaceuticalValeant Pharmaceuticals

Sinclair IS buys derma company


UK specialty drugmaker Sinclair IS Pharma plc (AIM: SPH.L) has entered into an agreement to acquire USA-based…

Advanced Bio-TechnologiesDermatologicalsKelo-coteMergers & AcquisitionsPharmaceuticalSinclair IS Pharma

USA’s SOHM acquires Novatrend to expand presence in India


California, USA-based generic drugmaker SOHM (Pinksheets: SHMN) has announced the acquisition of business…

Asia-PacificDermatologicalsGenericsMergers & AcquisitionsNovatrend MedicamentPharmaceuticalSOHM

Pfizer to buy Excaliard, gaining rights to Ph II skin scarring product


Global pharma behemoth Pfizer (NYSE: PFE) says it has entered into a definitive agreement to acquire…

DermatologicalsExcaliard PharmaIsis PharmaceuticalsMergers & AcquisitionsPfizerPharmaceutical

46% of US dermatologists expect to prescribe Pfizer’s tofacitinib to psoriasis patients who failed one biologic


In the first year following its approval for psoriasis, nearly one-half (46%) of surveyed dermatologists…

apremilastCelgeneDermatologicalsMarkets & MarketingNorth AmericaPfizerPharmaceuticaltofacitinib

Invida acquires portfolio of derma and primary care products from Shalaks for marketing in India


Singapore-headquartered Invida Holdings, a leading specialty biopharmaceutical company focused on the…

Asia-PacificDermatologicalsInvidaMergers & AcquisitionsPharmaceuticalShalaks Pharma

Psoriasis drug market set to see strong growth until 2018, reaching a value of $6.7 million


The psoriasis therapeutics market is forecast to show high growth until 2018 and market research firm…

DermatologicalsGlobalImmunologicalsMarkets & MarketingPharmaceutical

Many European dermatologists want more post-marketing data before Rxing Pfizer’s Janus


At least half of surveyed dermatologists across the EU5 (France, Germany, Italy, Spain and the UK) will…

BiotechnologyDermatologicalsEuropeJanusMarkets & MarketingPfizerPharmaceuticaltofacitinib

Shire drops Dermagraft for venous leg ulcers, after Ph III failure


Ireland-headquartered drugmaker Shire (LSE: SHP) says that Advanced BioHealing (ABH), the USA-based regenerative…

Advanced BioHealingBiotechnologyDermagraftDermatologicalsPharmaceuticalRegulationResearchShire

Independent Nycomed US names ex-King Pharma execs as CEO, COO and CFO


Nycomed US Inc has announced the appointment of Brian Markison as president and chief executive Officer…

DermatologicalsKing PharmaceuticalsManagementNycomed USPharmaceutical

Allergan to acquire derma firm Vicept for up to $275 million


US drugmaker Allergan (NYSE: AGN) has entered into a definitive agreement for to acquire all of the outstanding…

AllerganDermatologicalsMergers & AcquisitionsPharmaceuticalVicept Therapeutics

Valeant to acquire J&J’s Ortho Dermatologics for $345 million


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has signed an…

DermatologicalsJohnson & JohnsonMergers & AcquisitionsOrtho-McNeil-JanssenPharmaceuticalValeant Pharmaceuticals

Valeant to buy Sanofi’s skin care unit Dermik for $425 million


Canada’s Valeant Pharmaceuticals International (TSX: VRX) has entered into an agreement to acquire…

DermatologicalsDermikMergers & AcquisitionsNorth AmericaPharmaceuticalSanofiValeant Pharmaceuticals

Spain’s Almirall launches Sativex and gets OK for Actikerall in Germany


Spain’s largest pharmaceutical firm, Almirall (ALM: MC) yesterday announced the German launch of…

ActikerallAlmirallDermatologicalsEuropeGW PharmaceuticalsMarkets & MarketingNeurologicalOncologyPharmaceuticalRegulationSativex

US pharma has 277 medicines in development for skin diseases


The USA’s biopharmaceutical research companies currently are developing 277 medicines to help the…

DermatologicalsNorth AmericaPharmaceuticalResearch

AstraZeneca gains rights to Heptares GPCR drug for $6.25 million upfront


Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has entered a four-year…

AstraZenecaDermatologicalsHeptares TherapeuticsLicensingNeurologicalPharmaceuticalResearch

100 to 117 of 117 results

Back to top